HC Wainwright & Co. Reiterates Buy on Iterum Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating for Iterum Therapeutics (NASDAQ:ITRM) and maintained a price target of $5.
September 10, 2024 | 10:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Iterum Therapeutics, maintaining a $5 price target. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $5 price target by a reputable analyst firm like HC Wainwright & Co. indicates a positive outlook for Iterum Therapeutics. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100